奥拉帕利联合度伐利尤单抗治疗胚系BRCA突变转移性乳腺癌(MEDIOLA):开放标签、多中心、1/2期篮式研究
MEDIOLA是一项多中心、开放标签、1/2期篮式研究,评估奥拉帕利联合PD-L1抑制剂度伐利尤单抗在胚系BRCA1/2突变、HER2阴性转移性乳腺癌患者中的安全性和活性。34例患者接受治疗,11例(32%)发生≥3级不良事件,最常见为贫血(12%)、中性粒细胞减少(9%)和胰腺炎(6%)。30例可评估患者中24例(80%;结论认为该联合方案显示出有前景的抗肿瘤活性,安全性与此前奥拉帕利和度伐利尤单抗单药研究相似。
要点
- ≥3级不良事件发生率32%,最常见为贫血(12%)、中性粒细胞减少(9%)和胰腺炎(6%)。
- 3例(9%)因不良事件停药,4例(12%)发生共6例次严重不良事件,无治疗相关死亡。
核心结论
- 奥拉帕利联合度伐利尤单抗在胚系BRCA突变转移性乳腺癌中显示出有前景的抗肿瘤活性和可接受的安全性。
研究设计与样本
- MEDIOLA为多中心、开放标签、1/2期篮式研究,纳入胚系BRCA1/2突变、HER2阴性、进展性转移性乳腺癌患者,来自英国、美国、以色列、法国、瑞士和韩国14个中心。
- 主要终点为安全性和耐受性以及12周疾病控制率;安全性分析纳入至少接受一剂研究治疗的患者,活性分析在全分析集中进行。
- 2016年6月14日至2017年5月2日共34例患者入组并接受两种研究药物,纳入安全性分析。
主要发现
- 11例(32%)患者发生≥3级不良事件,最常见为贫血(4例[12%])、中性粒细胞减少(3例[9%])和胰腺炎(2例[6%])。
- 3例(9%)患者因不良事件停药,4例(12%)患者共发生6例次严重不良事件,无治疗相关死亡。
关键数值与推荐
- 入组标准:年龄≥18岁(韩国≥19岁),胚系BRCA1/2突变,组织学确诊的进展性HER2阴性转移性乳腺癌,既往转移性乳腺癌化疗线数不超过2线。
- 主要终点:安全性和耐受性,以及12周疾病控制率。
临床怎么用
- 该联合方案在胚系BRCA突变转移性乳腺癌中显示出较高的12周疾病控制率,支持进一步随机研究验证。
- 需关注贫血、中性粒细胞减少和胰腺炎等不良事件,必要时调整治疗。
- 目前证据尚不足以常规推荐该联合方案,需等待随机对照研究确定获益预测因素及是否优于奥拉帕利单药。
局限性
- 本研究为单臂、开放标签、1/2期篮式研究,无随机对照,样本量较小(34例),结论需进一步随机研究验证。
- 原文未报告无进展生存期、总生存期等长期疗效数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Poly (ADP-ribose) polymerase inhibitors combined with immunotherapy have shown antitumour activity in preclinical studies. We aimed to assess the safety and activity of olaparib in combination with the PD-L1-inhibitor, durvalumab, in patients with germline BRCA1-mutated or BRCA2-mutated metastatic breast cancer. METHODS: The MEDIOLA trial is a multicentre, open-label, phase 1/2, basket trial of durvalumab and olaparib in solid tumours. Patients were enrolled into four initial cohorts: germline BRCA-mutated, metastatic breast cancer; germline BRCA-mutated, metastatic ovarian cancer; metastatic gastric cancer; and relapsed small-cell lung cancer. Here, we report on the cohort of patients with breast cancer. Patients who were aged 18 years or older (or aged 19 years or older in South Korea) with germline BRCA1-mutated or BRCA2-mutated or both and histologically confirmed, progressive, HER2-negative, metastatic breast cancer were enrolled from 14 health centres in the UK, the USA, Israel, France, Switzerland, and South Korea. Patients should not have received more than two previous lines of chemotherapy for metastatic breast cancer. Patients received 300 mg olaparib in tablet form orally twice daily for 4 weeks and thereafter a combination of olaparib 300 mg twice daily and durvalumab 1·5 g via intravenous infusion every 4 weeks until disease progression. Primary endpoints were safety and tolerability, and 12-week disease control rate. Safety was analysed in patients who received at least one dose of study treatment, and activity analyses were done in the full-analysis set (patients who received at least one dose of study treatment and were not excluded from the study). Recruitment has completed and the study is ongoing. This trial is registered with ClinicalTrials.gov, NCT02734004. FINDINGS: Between June 14, 2016, and May 2, 2017, 34 patients were enrolled and received both study drugs and were included in the safety analysis. 11 (32%) patients experienced grade 3 or worse adverse events, of which the most common were anaemia (four [12%]), neutropenia (three [9%]), and pancreatitis (two [6%]). Three (9%) patients discontinued due to adverse events and four (12%) patients experienced a total of six serious adverse events. There were no treatment-related deaths. 24 (80%; 90% CI 64·3-90·9) of 30 patients eligible for activity analysis had disease control at 12 weeks. INTERPRETATION: Combination of olaparib and durvalumab showed promising antitumour activity and safety similar to that previously observed in olaparib and durvalumab monotherapy studies. Further research in a randomised setting is needed to determine predictors of therapeutic benefit and whether addition of durvalumab improves long-term clinical outcomes compared with olaparib monotherapy. FUNDING: AstraZeneca.
引用
- Domchek SM, Postel-Vinay S, Im SA, et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol. 2020. PMID: 32771088. doi:10.1016/S1470-2045(20)30324-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。